Clinical trial
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary…
NCT00423592 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00423592 |
|---|---|
| Title | Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension |
| Official title | A Phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects With Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | ambrisentan |
| Enrollment | 36 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Mar 1, 2009 |
| First posted | Jan 18, 2007 |
| Last update posted | Jun 17, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: